Holen Sie sich die Stockscreener-App
22.53
0.40%
-0.09
Vorhandelsmarkt:
22.50
-0.03
-0.13%
Schlusskurs vom Vortag:
$22.62
Offen:
$22.55
24-Stunden-Volumen:
2.08M
Relative Volume:
1.00
Marktkapitalisierung:
$3.80B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
125.17
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
+5.33%
1M Leistung:
+5.68%
6M Leistung:
+56.13%
1J Leistung:
+52.85%
1-Tages-Spanne:
$22.05
$22.92
1-Wochen-Bereich:
$21.07
$23.05
52-Wochen-Spanne:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.53 | 3.82B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.21 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.91 | 69.37B | 14.25B | 4.58B | 3.56B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.59 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
821.97 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.95 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Activity Recap & Precise Buy Zone Tips - newser.com
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204 - TipRanks
Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekers - newser.com
Why ACADIA Pharmaceuticals Inc. stock remains undervaluedMarket Sentiment Review & Community Trade Idea Sharing - newser.com
Allianz Asset Management GmbH Has $369,000 Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Ranking ACADIA Pharmaceuticals Inc. among high performing stocks via toolsRisk Management & Daily Growth Stock Tips - newser.com
Understanding ACADIA Pharmaceuticals Inc.’s price movementJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - newser.com
Acadia Pharmaceuticals (NASDAQ: ACAD) to Join UBS and Jefferies Healthcare Conferences - Stock Titan
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire
Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect? - sharewise.com
Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is ACADIA Pharmaceuticals Inc. stock a top momentum play2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
How ACADIA Pharmaceuticals Inc. stock performs after earningsRecession Risk & Long-Term Safe Investment Plans - newser.com
How ACADIA Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Patterns & Reliable Volume Spike Alerts - newser.com
Real time alert setup for ACADIA Pharmaceuticals Inc. performanceIPO Watch & Long-Term Investment Growth Plans - newser.com
Is ACADIA Pharmaceuticals Inc. stock supported by strong fundamentalsMarket Risk Summary & Weekly Momentum Stock Picks - newser.com
Why ACADIA Pharmaceuticals Inc. stock is rated strong buyWeekly Volume Report & High Yield Equity Trading Tips - newser.com
ACADIA Pharmaceuticals Advances Phase 2 Study of ACP-204 for Lewy Body Dementia Psychosis - TipRanks
Is ACADIA Pharmaceuticals Inc. stock trading near support levels2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Glioblastoma Multiforme Pipeline 2025: MOA and ROA Insights, - openPR.com
Glioblastoma Multiforme Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic - Barchart.com
ACADIA’s ACP-204 Study: A Promising Step for Alzheimer’s Disease Psychosis Treatment - TipRanks
ACADIA Pharmaceuticals Advances Study on Carbetocin Nasal Spray for Prader-Willi Syndrome - TipRanks
ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment - TipRanks
Merger Talk: What catalysts could drive ACADIA Pharmaceuticals Inc. stock higherEntry Point & Fast Gaining Stock Strategy Reports - Fundação Cultural do Pará
Is ACADIA Pharmaceuticals Inc. reversing from oversold territoryEarnings Beat & Intraday High Probability Alerts - newser.com
How sentiment analysis helps forecast ACADIA Pharmaceuticals Inc.Jobs Report & Growth Focused Investment Plans - newser.com
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
1.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):